Please assess the completion status of the following clinical trial:

Trial Title: The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~Filter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines:~* Healthy subjects aged 16 and older as established by medical history and clinical examination~* The subjects or their guardians are able to understand and sign the informed consent~* Had never received the hepatitis B vaccines~* Subjects who can and will comply with the requirements of the protocol~Revaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines:~* Healthy subjects aged 16 and older as established by medical history and clinical examination~* The subjects or their guardians are able to understand and sign the informed consent~* After the routine administration of 10mcg hepatitis B vaccines, the peak period levels of anti-HBs is lower than 10mIU/ml~* Subjects with temperature \<37.1°C on axillary setting~* Subjects who can and will comply with the requirements of the protocol~Exclusion Criteria:~Filter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines:~* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine~* Family history of seizures or progressive neurological disease~* Family history of congenital or hereditary immunodeficiency~* Women of pregnancy, lactation or about to be pregnant in 60 days~* Autoimmune disease or immunodeficiency~* Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws~* Any prior administration of administration of immunoglobulins~Filter period: The subjects to receive second or/and third 10mcg recombinant hepatitis B vaccines:~* Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations~* Serious adverse reactions to vaccines~* Active infections~* Subjects who want to quit the study~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives~Revaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines:~* Qualitative test of Anti-HBs, HBsAg or Anti-HBc on serum is positive~* Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations~* Family history of seizures or progressive neurological disease~* Family history of congenital or hereditary immunodeficiency~* Women of pregnancy, lactation or about to be pregnant in 60 days~* Autoimmune disease or immunodeficiency~* Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws~* Any prior administration of immunoglobulins, any other vaccines or experimental drugs in the last 7days~* Any active infections and received any antibiotic or anti-virus treatments in the last 7 days~* Had a fever in the last 3 days, with temperature ≥37.1°C~* Participate in another clinical trials~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives~Revaccination period: The nonresponders to receive second or/and third 60mcg recombinant hepatitis B vaccines:~* Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations~* Serious adverse reactions to vaccines~* Active infections~* Subjects who want to quit the study~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 60mcg/1.0ml recombinant hepatitis B vaccine (Type: EXPERIMENTAL): 600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
- 30mcg/1.0ml recombinant hepatitis B vaccine (Type: EXPERIMENTAL): 600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
- 10mcg/1.0ml recombinant hepatitis B vaccine (Type: PLACEBO_COMPARATOR): 300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete